Trade AcelRx - ACRX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0246 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 0.01 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 0.6869 |
Open* | 0.6469 |
1-Year Change* | 115.63% |
Day's Range* | 0.6389 - 0.7367 |
52 wk Range | 0.16-0.95 |
Average Volume (10 days) | 589.82K |
Average Volume (3 months) | 46.02M |
Market Cap | 31.41M |
P/E Ratio | 0.74 |
Shares Outstanding | 147.33M |
Revenue | 2.88M |
EPS | 0.29 |
Dividend (Yield %) | N/A |
Beta | 0.45 |
Next Earnings Date | Nov 14, 2022 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2023 | 0.7367 | 0.0898 | 13.88% | 0.6469 | 0.7548 | 0.6369 |
Mar 24, 2023 | 0.6869 | 0.0001 | 0.01% | 0.6868 | 0.6968 | 0.6519 |
Mar 23, 2023 | 0.7068 | -0.0099 | -1.38% | 0.7167 | 0.7230 | 0.6639 |
Mar 22, 2023 | 0.7208 | 0.0569 | 8.57% | 0.6639 | 0.8763 | 0.6639 |
Mar 21, 2023 | 0.6819 | 0.0867 | 14.57% | 0.5952 | 0.6851 | 0.5683 |
Mar 20, 2023 | 0.5872 | -0.0597 | -9.23% | 0.6469 | 0.6469 | 0.5472 |
Mar 17, 2023 | 0.6469 | -0.0409 | -5.95% | 0.6878 | 0.7068 | 0.6369 |
Mar 16, 2023 | 0.6868 | 0.0004 | 0.06% | 0.6864 | 0.7118 | 0.6371 |
Mar 15, 2023 | 0.7068 | -0.1126 | -13.74% | 0.8194 | 0.8194 | 0.6069 |
Mar 14, 2023 | 0.8648 | -0.3106 | -26.43% | 1.1754 | 1.2252 | 0.8494 |
Mar 13, 2023 | 1.0757 | -0.0398 | -3.57% | 1.1155 | 1.1654 | 1.0557 |
Mar 10, 2023 | 1.1554 | -0.0100 | -0.86% | 1.1654 | 1.1854 | 1.0955 |
Mar 9, 2023 | 1.1455 | 0.0001 | 0.01% | 1.1454 | 1.1754 | 1.1055 |
Mar 8, 2023 | 1.1654 | -0.0498 | -4.10% | 1.2152 | 1.2252 | 1.1454 |
Mar 7, 2023 | 1.1953 | -0.0798 | -6.26% | 1.2751 | 1.2851 | 1.1653 |
Mar 6, 2023 | 1.2751 | -0.0299 | -2.29% | 1.3050 | 1.3149 | 1.2351 |
Mar 3, 2023 | 1.2851 | 0.0100 | 0.78% | 1.2751 | 1.2950 | 1.2551 |
Mar 2, 2023 | 1.2751 | -0.0299 | -2.29% | 1.3050 | 1.3249 | 1.2451 |
Mar 1, 2023 | 1.2950 | -0.0997 | -7.15% | 1.3947 | 1.4147 | 1.2950 |
Feb 28, 2023 | 1.3847 | 0.0099 | 0.72% | 1.3748 | 1.4047 | 1.3548 |
AcelRx Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total revenue | 2.818 | 5.416 | 2.289 | 2.151 | 7.995 |
Revenue | 2.818 | 5.416 | 2.289 | 2.151 | 7.995 |
Cost of Revenue, Total | 3.753 | 6.032 | 6.806 | 3.976 | 10.659 |
Gross Profit | -0.935 | -0.616 | -4.517 | -1.825 | -2.664 |
Total Operating Expense | 38.783 | 46.379 | 56.494 | 37.878 | 46.677 |
Selling/General/Admin. Expenses, Total | 30.935 | 36.33 | 45.027 | 20.765 | 16.609 |
Research & Development | 4.095 | 4.017 | 4.661 | 13.137 | 19.409 |
Unusual Expense (Income) | 0 | ||||
Operating Income | -35.965 | -40.963 | -54.205 | -35.727 | -38.682 |
Interest Income (Expense), Net Non-Operating | -2.167 | -2.722 | -0.369 | -1.079 | -2.806 |
Other, Net | 3.038 | 3.31 | 1.337 | -10.341 | -10.721 |
Net Income Before Taxes | -35.094 | -40.375 | -53.237 | -47.147 | -52.209 |
Net Income After Taxes | -35.099 | -40.379 | -53.24 | -47.149 | -17.405 |
Net Income Before Extra. Items | -35.099 | -40.379 | -53.24 | -47.149 | -17.405 |
Net Income | -35.099 | -40.379 | -53.24 | -47.149 | -51.508 |
Income Available to Common Excl. Extra. Items | -35.099 | -40.379 | -53.24 | -47.149 | -17.405 |
Income Available to Common Incl. Extra. Items | -35.099 | -40.379 | -53.24 | -47.149 | -51.508 |
Diluted Net Income | -35.099 | -40.379 | -53.24 | -47.149 | -51.508 |
Diluted Weighted Average Shares | 119.86 | 85.257 | 79.1843 | 58.4086 | 46.8835 |
Diluted EPS Excluding Extraordinary Items | -0.29283 | -0.47362 | -0.67236 | -0.80723 | -0.37124 |
Diluted Normalized EPS | -0.29387 | -0.47362 | -0.67236 | -0.80723 | -0.37124 |
Total Extraordinary Items | 0 | -34.103 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total revenue | 0.442 | 0.002 | 1.862 | 0.443 | 0.511 |
Revenue | 0.442 | 0.002 | 1.862 | 0.443 | 0.511 |
Cost of Revenue, Total | 0.784 | 1.234 | 0.439 | 1.04 | 1.04 |
Gross Profit | -0.342 | -1.232 | 1.423 | -0.597 | -0.529 |
Total Operating Expense | 9.437 | 8.177 | 10.495 | 10.458 | 9.653 |
Selling/General/Admin. Expenses, Total | 7.338 | 5.957 | 8.64 | 8.694 | 7.644 |
Research & Development | 1.315 | 0.986 | 1.416 | 0.724 | 0.969 |
Operating Income | -8.995 | -8.175 | -8.633 | -10.015 | -9.142 |
Interest Income (Expense), Net Non-Operating | -0.352 | -0.435 | -0.506 | -0.63 | -0.596 |
Other, Net | 0.673 | 0.693 | 0.764 | 0.799 | 0.782 |
Net Income Before Taxes | -8.674 | -7.917 | -8.375 | -9.846 | -8.956 |
Net Income After Taxes | -8.674 | -7.917 | -8.375 | -9.851 | -8.956 |
Net Income Before Extra. Items | -8.674 | -7.917 | -8.375 | -9.851 | -8.956 |
Net Income | -8.674 | -7.917 | -8.375 | -9.851 | -8.956 |
Income Available to Common Excl. Extra. Items | -8.674 | -7.917 | -8.375 | -9.851 | -8.956 |
Income Available to Common Incl. Extra. Items | -8.674 | -7.917 | -8.375 | -9.851 | -8.956 |
Diluted Net Income | -8.674 | -7.917 | -8.375 | -9.851 | -8.956 |
Diluted Weighted Average Shares | 145.624 | 127.774 | 119.224 | 119.12 | 113.257 |
Diluted EPS Excluding Extraordinary Items | -0.05956 | -0.06196 | -0.07025 | -0.0827 | -0.07908 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.05956 | -0.06196 | -0.07025 | -0.08089 | -0.08369 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 55.489 | 46.83 | 71.688 | 107.994 | 63.413 |
Cash and Short Term Investments | 51.63 | 42.886 | 66.137 | 105.715 | 60.469 |
Cash & Equivalents | 12.663 | 27.274 | 14.684 | 87.975 | 52.902 |
Short Term Investments | 38.967 | 15.612 | 51.453 | 17.74 | 7.567 |
Total Receivables, Net | 0.16 | 0.635 | 0.52 | 0.401 | 1.533 |
Accounts Receivable - Trade, Net | 0.16 | 0.635 | 0.432 | 0.049 | 1.533 |
Total Inventory | 1.111 | 1.626 | 3.295 | 0.854 | 0.956 |
Prepaid Expenses | 2.588 | 1.683 | 1.736 | 1.024 | 0.455 |
Total Assets | 77.893 | 66.295 | 91.356 | 120.533 | 75.552 |
Property/Plant/Equipment, Total - Net | 20.23 | 18.809 | 18.48 | 11.483 | 11.051 |
Property/Plant/Equipment, Total - Gross | 31.016 | 29.398 | 28.032 | 20.427 | 19.489 |
Accumulated Depreciation, Total | -10.786 | -10.589 | -9.552 | -8.944 | -8.438 |
Other Long Term Assets, Total | 2.174 | 0.656 | 0.925 | 0.705 | 0.385 |
Total Current Liabilities | 18.509 | 17.635 | 13.611 | 15.928 | 13.66 |
Accounts Payable | 2.121 | 2.737 | 1.72 | 2.07 | 1.424 |
Accrued Expenses | 7.506 | 6.008 | 6.498 | 4.54 | 3.543 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 8.796 | 8.841 | 4.982 | 9.003 | 8.331 |
Other Current Liabilities, Total | 0.086 | 0.049 | 0.411 | 0.315 | 0.362 |
Total Liabilities | 113.786 | 122.045 | 132.774 | 116.28 | 112.061 |
Total Long Term Debt | 5.007 | 13.14 | 20.517 | 3.38 | 11.369 |
Long Term Debt | 5.007 | 13.14 | 20.517 | 3.38 | 11.369 |
Other Liabilities, Total | 90.27 | 91.27 | 98.646 | 96.972 | 87.032 |
Total Equity | -35.893 | -55.75 | -41.418 | 4.253 | -36.509 |
Common Stock | 0.137 | 0.098 | 0.079 | 0.078 | 0.051 |
Additional Paid-In Capital | 437.554 | 382.637 | 356.609 | 349.194 | 261.31 |
Retained Earnings (Accumulated Deficit) | -473.584 | -438.485 | -398.106 | -345.019 | -297.87 |
Other Equity, Total | 0 | ||||
Total Liabilities & Shareholders’ Equity | 77.893 | 66.295 | 91.356 | 120.533 | 75.552 |
Total Common Shares Outstanding | 136.82 | 98.812 | 79.5731 | 78.7579 | 50.8992 |
Note Receivable - Long Term | 0.263 | 0.351 | 0.703 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 42.811 | 55.489 | 51.753 | 58.97 | 71.315 |
Cash and Short Term Investments | 39.349 | 51.63 | 48.699 | 55.325 | 67.345 |
Cash & Equivalents | 21.822 | 12.663 | 13.271 | 26.327 | 34.363 |
Short Term Investments | 17.527 | 38.967 | 35.428 | 28.998 | 32.982 |
Total Receivables, Net | 0.184 | 0.16 | 0.153 | 0.104 | 0.658 |
Accounts Receivable - Trade, Net | 0.184 | 0.16 | 0.153 | 0.104 | 0.658 |
Total Inventory | 1.045 | 1.111 | 1.556 | 1.363 | 1.419 |
Prepaid Expenses | 2.233 | 2.588 | 1.345 | 2.178 | 1.893 |
Total Assets | 71.971 | 77.893 | 72.263 | 79.586 | 87.347 |
Property/Plant/Equipment, Total - Net | 20.08 | 20.23 | 20.229 | 20.546 | 15.962 |
Other Long Term Assets, Total | 0.261 | 2.174 | 0.281 | 0.07 | 0.07 |
Total Current Liabilities | 17.033 | 18.509 | 17.07 | 15.188 | 15.544 |
Accounts Payable | 2.715 | 2.121 | 2.228 | 1.941 | 3.235 |
Accrued Expenses | 5.505 | 7.592 | 6.062 | 4.483 | 3.528 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 8.813 | 8.796 | 8.78 | 8.764 | 8.781 |
Other Current Liabilities, Total | 0 | ||||
Total Liabilities | 110.244 | 113.786 | 115.284 | 115.575 | 114.659 |
Total Long Term Debt | 3.041 | 5.007 | 6.952 | 9.374 | 11.265 |
Long Term Debt | 3.041 | 5.007 | 6.952 | 9.374 | 11.265 |
Other Liabilities, Total | 90.17 | 90.27 | 91.262 | 91.013 | 87.85 |
Total Equity | -38.273 | -35.893 | -43.021 | -35.989 | -27.312 |
Common Stock | 0.147 | 0.137 | 0.119 | 0.119 | 0.118 |
Additional Paid-In Capital | 443.838 | 437.554 | 422.527 | 421.184 | 420.011 |
Retained Earnings (Accumulated Deficit) | -482.258 | -473.584 | -465.667 | -457.292 | -447.441 |
Total Liabilities & Shareholders’ Equity | 71.971 | 77.893 | 72.263 | 79.586 | 87.347 |
Total Common Shares Outstanding | 147.109 | 136.82 | 119.317 | 119.18 | 119.103 |
Intangibles, Net | 8.819 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -35.099 | -40.379 | -53.24 | -47.149 | -51.508 |
Cash From Operating Activities | -30.002 | -38.505 | -51.18 | -29.075 | -29.765 |
Cash From Operating Activities | 1.973 | 1.853 | 1.668 | 0.575 | 1.744 |
Non-Cash Items | 2.921 | 2.309 | 4.298 | 15.632 | 16.3 |
Cash Taxes Paid | 0.005 | -0.347 | -0.35 | 0.002 | 0.002 |
Cash Interest Paid | 1.595 | 2.269 | 1.712 | 1.667 | 2.043 |
Changes in Working Capital | 0.203 | -2.288 | -3.906 | 1.867 | 3.699 |
Cash From Investing Activities | -26.123 | 34.139 | -36.563 | -10.877 | -9.97 |
Capital Expenditures | -1.827 | -1.855 | -3.47 | -0.819 | -2.405 |
Other Investing Cash Flow Items, Total | -24.296 | 35.994 | -33.093 | -10.058 | -7.565 |
Cash From Financing Activities | 41.514 | 16.956 | 14.452 | 75.025 | 12.327 |
Financing Cash Flow Items | 5.313 | -0.086 | -9.054 | 0 | -0.204 |
Issuance (Retirement) of Stock, Net | 45.034 | 21.709 | 1.976 | 82.743 | 16.045 |
Issuance (Retirement) of Debt, Net | -8.833 | -4.667 | 21.53 | -7.718 | -3.514 |
Net Change in Cash | -14.611 | 12.59 | -73.291 | 35.073 | -27.408 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -8.674 | -35.099 | -27.182 | -18.807 | -8.956 |
Cash From Operating Activities | -8.934 | -30.002 | -21.998 | -18.055 | -9.708 |
Cash From Operating Activities | 0.42 | 1.973 | 1.512 | 1.029 | 0.45 |
Non-Cash Items | 0.246 | 2.921 | 1.75 | 0.966 | 0.03 |
Changes in Working Capital | -0.926 | 0.203 | 1.922 | -1.243 | -1.232 |
Cash From Investing Activities | 20.176 | -26.123 | -21.684 | -15.032 | -17.425 |
Capital Expenditures | -0.089 | -1.827 | -1.799 | -1.615 | -0.024 |
Other Investing Cash Flow Items, Total | 20.265 | -24.296 | -19.885 | -13.417 | -17.401 |
Cash From Financing Activities | -2.083 | 41.514 | 29.679 | 32.14 | 34.222 |
Financing Cash Flow Items | -0.058 | 5.313 | -0.249 | -0.249 | -0.249 |
Issuance (Retirement) of Stock, Net | 0.058 | 45.034 | 36.678 | 36.556 | 36.554 |
Issuance (Retirement) of Debt, Net | -2.083 | -8.833 | -6.75 | -4.167 | -2.083 |
Net Change in Cash | 9.159 | -14.611 | -14.003 | -0.947 | 7.089 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group500K+
Traders
92K+
Active clients monthly
$53M+
Monthly investing volume
$30M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AcelRx Company profile
AcelRxIndustry: | Bio Therapeutic Drugs |
25821 Industrial Boulevard
Suite 400
94545
Income Statement
- Annual
- Quarterly
News

GBP/EUR forecast: Will the pound rise against the euro in 2023?
The British pound has been moving sideways against the Euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
16:27, 24 March 2023
Shiba Inu price prediction: Can the meme coin build on recent gains?
What’s next for the Shiba Inu meme coin after a sluggish 2022 so far? Read more…
12:51, 24 March 2023
Who are the biggest bitcoin mining companies?
Bitcoin mining is big business, but who are the biggest bitcoin mining companies?
12:06, 24 March 2023
USD/PKR forecast: Will Pakistan’s rupee continue to fall?
The rupee has rebounded against the dollar in recent months, will this trend continue?
11:49, 24 March 2023
Amazon stock forecast: Where next for AMZN amid massive layoffs?
Amazon has been making tens of thousands of its workers redundant. Does this affect the market’s baseline Amazon stock forecast?
10:46, 24 March 2023
Sweatcoin price prediction: What is Sweatcoin?
Can Sweatcoin run to the front of the crypto pack?
15:19, 23 March 2023
Who owns the most bitcoin?
Want to know who owns the most bitcoin? Learn more about the biggest bitcoin whales.
14:54, 23 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com